Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. 71% achieved a >30% reduction in UP/Cr, a key indicator of kidney damage. 71% demonstrated improved or stabilized eGFR, signaling preserved kidney function. 37.5% had increased urinary VEGF levels, suggesting better blood vessel support in the kidneys. 36% had reduced urinary synaptopodin losses, indicating healthier kidney cells and structure. CRANBURY, N.J., A ...